Skip to main content

Advertisement

Log in

Regulation of oxygen–glucose deprivation/reperfusion-induced inflammatory responses and M1-M2 phenotype switch of BV2 microglia by lobetyolin

  • Original Article
  • Published:
Metabolic Brain Disease Aims and scope Submit manuscript

Abstract  

To elucidate the protective mechanism of lobetyolin on oxygen–glucose deprivation/reperfusion (OGD/R)-induced damage in BV2 microglial cells. The OGD/R model was established using a chemical modeling method to simulate in vivo brain ischemia in lobetyolin-pretreated BV2 cells. The optimum lobetyolin dosage, chemical concentration, and OGD/R modeling duration were screened. The changes in cell morphology were observed, and the levels of immune response-related factors, including tumor necrosis factor-α (TNF-α), interleukin-6, inducible nitric oxide synthase (iNOS), and cluster of differentiation (CD)206, were detected using the enzyme-linked immunosorbent assay. The expression of chemokine-like-factor-1 (CKLF1), hypoxia-inducible factor (HIF)-1α, TNF-α, and CD206, was detected using western blotting. The gene expression of M1 and M2 BV2 phenotype markers was assessed using quantitative polymerase chain reaction (qPCR). The localization of M1 and M2 BV2 markers was detected using immunofluorescence analysis. The results showed that lobetyolin could protect BV2 cells from OGD/R-induced damage. After OGD/R, CKLF1/C–C chemokine receptor type 4 (CCR4) levels increased in BV2 cells, whereas the CKLF1/CCR4 level was decreased due to lobetyolin pretreatment. Additionally, BV2 cells injured with OGD/R tended to be M1 type, but lobetyolin treatment shifted the phenotype of BV2 cells from M1 type to M2 type. Lobetyolin decreased the expression of TNF-α and HIF-1α but increased the expression of transforming growth factor-β (TGF-β) in BV2 cells, indicating a dose–effect relationship. The qPCR results showed that lobetyolin decreased the expression of CD16, CD32, and iNOS at the gene level and increased the expression of C–C-chemokine ligand-22 and TGF-β. The immunofluorescence analysis showed that lobetyolin decreased CD16/CD32 levels and increased CD206 levels. Lobetyolin can protect BV2 cells from OGD/R-induced damage by regulating the phenotypic polarization of BV2 and decreasing inflammatory responses. Additionally, CKLF1/CCR4 may participate in regulating lobetyolin-induced polarization of BV2 cells via the HIF-1α pathway.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10

Similar content being viewed by others

Data availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Abbreviations

OGD/R:

Oxygen glucose deprivation/re-oxygenaion

CKLFI:

Chemokine-like-factor 1

CCR4:

C-C chemokine receptor type 4

HIF-1α:

Hypoxiainduciblefactor-1α

TGF-β:

Transforming growth factor beta

TNF- α:

Tumor necrosis factor- α

CD-16:

Cluster of differentiation-16

CD32:

Cluster of differentiation-32

CD206:

Cluster of differentiation-206

CCL-22:

CC-chemokine ligand-22

IL-1β:

Interleukin-1β

IL-2:

Interleukin-2

IL-4:

Interleukin-4

IL-6:

Interleukin-6

IL-10:

Interleukin-10

IL-12:

Interleukin-12

IL-23:

Interleukin-23

IL-1Ra:

Interleukin-1Ra

iNOS:

Inducible nitric oxide synthase

VEGF-A:

Vascular endothelial growth factor-A

CCK-8:

Cell Counting Kit-8

ELISA:

Enzyme-Linked immunosorbent assay

qPCR:

Quantitative PCR Detecting System

WB:

Western blot

Eda:

Edaravonc

CCI:

Chronic Cerebral ischemia

References:

Download references

Acknowledgements

This research was supported by grants from National Natural Science Foundation of China (U21A20410), (81874420), (82274388), (82004236); Key Program of Shanxi Province (International Science and Technology Cooperation) Major regional innovation cooperation project (201803D421006) , (201903D421018) .

Funding

This research was supported by grants from National Natural Science Foundation of China (U21A20410), (81874420), (82274388), (82004236); Key Program of Shanxi Province (International Science and Technology Cooperation) Major regional innovation cooperation project (201803D421006),(201903D421018).

Author information

Authors and Affiliations

Authors

Contributions

Junlong Zhang, Wenbin He, and Jie Wang developed the study conception and design. Wenyi Wei, Xin Liu and Jie Wang performed the experiment. Shifeng Chu, Jing Yang and Qinqing Li carried out the data analysis. Junlong Zhang, Wenbin He, Pulin Liu and Jie Wang developed the statistical analysis. The first draft of the manuscript was written by Junlong Zhang, Wenbin He, and Jie Wang. Xin Liu and Shifeng Chu conducted the written review. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Junlong Zhang or Wenbin He.

Ethics declarations

Competing interests

The authors declare that they have no competing.

interests.

Ethics approval

All studies were approved by the Care Committee of Shanxi University of Chinese Medicine (Jinzhong, China).

Consent to participate

Not applicable.

Consent to publish

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, J., Liu, X., Wei, W. et al. Regulation of oxygen–glucose deprivation/reperfusion-induced inflammatory responses and M1-M2 phenotype switch of BV2 microglia by lobetyolin. Metab Brain Dis 38, 2627–2644 (2023). https://doi.org/10.1007/s11011-023-01292-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11011-023-01292-6

Keywords

Navigation